暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
GPCR 硕迪生物
- 38.940
- -0.040-0.10%
收盘价 04/26 16:00 (美东)
- 38.900
- -0.040-0.10%
盘后 16:27 (美东)
18.15亿总市值-20155市盈率TTM
39.460最高价37.850最低价97.26万股成交量39.020今开38.980昨收3718.65万成交额2.53%换手率亏损市盈率(静)4661.88万总股本75.01752周最高4.01市净率14.95亿流通值21.79052周最低--股息TTM3840.44万流通股75.017历史最高--股息率TTM4.13%振幅20.800历史最低38.234平均价1股每手
盘后分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
抖音将限制减肥药的推广
根据视频共享网站上周发布的新社区指南，流行的社交媒体平台TikTok将从下个月开始严厉打击大多数与减肥药相关的内容。
分析师看好这些医疗保健股：Corcept Therapeutics（CORT）、Structure Therapeutics, Inc.赞助的ADR（GPCR）
更多竞品来袭！Global Data：预计到2029年将有13款减肥新药上市
根据全球数据分析和咨询公司Global Data的一份新报告，由于对减肥产品的需求激增，制药商正准备在未来五年内在美国推出约13种新的减肥疗法。
在需求激增的情况下，到2029年，13种新的肥胖药物可能上市
Global Data的一份新报告显示，在对这些产品的需求激增的情况下，制药商正准备在未来五年内在美国推出估计13种新的减肥疗法。
快讯 | 坎托·菲茨杰拉德重申增持结构疗法，维持65美元的目标股价
由于即将到来的 GSBR-1290 第 2a 期数据乐观情绪，结构疗法的买入评级得到确认
评论
OBESITY Will only focus on main players $VKTX $LLY $NVO $AMGN $GPCR
$Viking Therapeutics(VKTX.US$$礼来(LLY.US$$诺和诺德(NVO.US$$安进(AMGN.US$$硕迪生物(GPCR.US$
Demand is too high for the obesity drugs but major drug companies unable to keep up with this demand. This will be an opportunity for multiple drug companies to take a pie out of the obesity market.
SubQ likely to be prescribed first for short term weight loss and oral drugs for maintenance. This is not an oncology space ...
Demand is too high for the obesity drugs but major drug companies unable to keep up with this demand. This will be an opportunity for multiple drug companies to take a pie out of the obesity market.
SubQ likely to be prescribed first for short term weight loss and oral drugs for maintenance. This is not an oncology space ...
9
3
Why does it seem relatively Dead
$硕迪生物(GPCR.US$
This stock seems to be looked past but these analysis have HIGH expectations. I think ill be entering soon. NFA
This stock seems to be looked past but these analysis have HIGH expectations. I think ill be entering soon. NFA
Leerink's David Risinger cheered the positive safety and efficacy results in obese patients, but market reaction tainted Structure's acquisition prospects.
1
Despite its rising cash burn rate, Structure Therapeutics remains in a secure financial state due to its focus on cash runway and low burn to market cap ratio. The company's strong cash runway and fund-raising potential mitigate concerns about its cash burn situation.
专栏Novo Nordisk Sets New Record High: Analyzing the Market Effects of Popular GLP-1 Weight Loss Drugs
The increasing demand for GLP-1 weight-loss medications indicates that in the next ten years, a significant number of Americans may lose hundreds of millions of pounds collectively. This shift in weight could cause a redistribution of trillions of dollars.
Last week, $诺和诺德(NVO.US$ presented evidence of a speeding trend when it announced that the primary component of Ozempic and Wegovy, ...
Last week, $诺和诺德(NVO.US$ presented evidence of a speeding trend when it announced that the primary component of Ozempic and Wegovy, ...
16
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
qkeep : Great sharing
103626360 : It seemed like viking will cross 120 in a week
SpyderCall : good stuff in this article